Results 111 to 120 of about 1,241,830 (150)

2018—2022年苏州地区血流感染患儿病原菌分布和耐药性分析

Zhongguo shiyan zhenduanxue
目的 探讨苏州地区住院患儿血流感染病原菌的分布和耐药特征，为该类患者的血流感染诊治提供依据。方法 回顾性分析2018年1月至2022年12月南京医科大学附属苏州医院血培养阳性患儿的临床资料、病原菌分布及其对抗菌药物的耐药情况。结果 896例血培养阳性患儿中，新生儿719例(占80.2%),非新生儿177例(占19.8%)。在分离出的926株病原菌中，以革兰阳性菌为主(65.9%),革兰阴性菌占33.4%,真菌仅占0.8%。最常见的病原菌为表皮葡萄球菌(32.6%),其次是头状葡萄球菌 ...
高晶晶, 周惠智, 苏宁, 袁垆, 陈海鹏, 许丽君, 徐卫东, 王亚南   +7 more
doaj  

[Distribution of the Pathogens Isolated from 6428 Tumor Patients in 2019-2023 and the Relevant Drug Resistance Surveillance Report]. [PDF]

Sichuan Da Xue Xue Bao Yi Xue Ban
Tang Q, Wang Y, Yuan Y, Shu L, Deng J, He C.   +5 more
europepmc   +1 more source

泻下药和解表药的现代药理解释

, 2007
目的在中药现代化的进程中,对中医药体系中的传统药效的现代药理学解释是一项有深远意义的工作。本实验设计了3种方法,在总体上对中药的传统药效与中药的现代药理活性进行对比分析,从中发现规律,对被研究的中药药效给出言之有据的解释。方法收集大量中药传统药效、中药现代药理活性和中药所含活性化合物现代药理活性数据,通过统计方法寻找特定中药药效类别(泻下和解表)的现代药理学的特征,从而得到其现代药理学解释。结果使用的3种方法都能够给出与2种药效相关的现代药理活性。汇总3种结果得到,泻下与导泄、兴奋胃肠平滑肌 ...
刘海波, 周家驹, 乔颖欣
core  

[Application of Nano-drug Delivery Technology in Overcoming Drug Resistance 
in Lung Cancer]. [PDF]

Zhongguo Fei Ai Za Zhi
Lu Y, Wang C, Liu B.
europepmc   +1 more source

[Chinese expert consensus on the diagnosis and treatment strategies for refractory/resistant cytomegalovirus infection in immunocompromised populations (2025)]. [PDF]

Zhonghua Xue Ye Xue Za Zhi
Infectiology Group, Chinese Society of Hematology, Chinese Medical Association, Chinese Society of Organ Transplantation, Chinese Society of Clinical Oncology Leukemia Expert Committee, Guangdong Medical Association of Respiratory Medicine, Guangdong Association of Primary Medicine Immunodeficiency Committee.   +6 more
europepmc   +1 more source

[METTL3-mediated m⁶A modification promotes FOXO3 expression and anthracycline resistance in acute myeloid leukemia cells through autophagy regulation]. [PDF]

Nan Fang Yi Ke Da Xue Xue Bao
Zhang X, Yang J, Wen Y, Liu Q, Dou L, Gao C.   +5 more
europepmc   +1 more source

Seasonal malaria chemoprevention effectiveness and drug resistance in Plasmodium falciparum: a matched parallel cohort study, Kenya. [PDF]

Bull World Health Organ
Rotich B, Kimachas E, Kipkoech J, Kirwa E, Markwalter C, Ekai D, Mwangi A, Van Hulle S, Menya D, O'Meara WP.   +9 more
europepmc   +1 more source

Future of PARP inhibitors in cancer treatment: overcoming resistance and enhancing efficacy with combination therapies. [PDF]

J Zhejiang Univ Sci B
Shoaib M, Bhutta ZA, Javed A, Amjad MN, Li W, Choi KC, Pu W.   +6 more
europepmc   +1 more source

[Epithelial-mesenchymal Transition: Biological Basis and Clinical Prospects 
of Lung Cancer Invasion, Metastasis, and Drug Resistance]. [PDF]

Zhongguo Fei Ai Za Zhi
Sun H, Xiong M, Xie S, Wen J.
europepmc   +1 more source